EE37 Cost-Utility Analysis of Elecsys Gaad Algorithm Versus Ultrasound Plus -Fetoprotein (AFP) for HCC Surveillance in Patients With Compensated Liver Cirrhosis in the United Kingdom (UK)

Abstract

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. National guidelines in the UK recommend biannual surveillance of high-risk groups using abdominal ultrasound (US) with or without AFP. Elecsys® GAAD is an approved in-vitro diagnostic digital tool that combines patient sex and age with Elecsys® AFP and Elecsys® protein induced by vitamin K absence-II (PIVKA-II) assay results to aid in the early detection of HCC. The objective of this study was to evaluate the cost-utility of GAAD versus US+AFP for HCC surveillance in patients with compensated liver cirrhosis in the UK